IL17A and liver dysplastic nodule: After activation, it can combine with other pathways, such as the TILs signaling pathway, to cause inflammation and fibrosis in the kidneys.[45,46] TP may treat DN by inhibiting local inflammation and excessive immunity in the kidney through the IL-17 signaling pathway, Toll-like receptor signaling pathway, Th1 and Th2 cell differentiation, NF-κB signaling pathway, etc.